ILiAD Biotechnologies: Funding, Investors & Team (Sep 2026)
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
ILiAD Biotechnologies has raised $158M across 2 funding rounds on record, the most recent a Series D of $115M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ILiAD Biotechnologies Company Profile and Key Stats
Latest funding round on record: Feb 2026.
ILiAD Biotechnologies Funding Rounds
ILiAD Biotechnologies raised $42.8M in a Series D announced in Sep 2022.
3.4 years later, a Series D of $115M was announced in Feb 2026.
ILiAD Biotechnologies Founders and Leadership Team
Contact details for the ILiAD Biotechnologies team: 1 of 1 has an email address on file.
Start 14-day free trial →ILiAD Biotechnologies Funding Compared to Other Biotechnology Startups
ILiAD Biotechnologies' latest round of $115M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ILiAD Biotechnologies in Biotechnology and New York
Companies Similar to ILiAD Biotechnologies
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
ILiAD Biotechnologies Funding FAQs
What does ILiAD Biotechnologies do?
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
How much funding has ILiAD Biotechnologies raised?
ILiAD Biotechnologies has raised $158M across 2 rounds on record. The most recent is a Series D of $115M announced in Feb 2026.
When did ILiAD Biotechnologies last raise funding?
ILiAD Biotechnologies' most recent funding round on record is a Series D of $115M, announced in Feb 2026.
Who is the CEO of ILiAD Biotechnologies?
Keith Rubin is listed as CEO at ILiAD Biotechnologies.
Where is ILiAD Biotechnologies headquartered?
ILiAD Biotechnologies is based in New York, United States.
How many employees does ILiAD Biotechnologies have?
ILiAD Biotechnologies is in the 11-50 employee band.
How does ILiAD Biotechnologies' funding compare to other Biotechnology startups?
ILiAD Biotechnologies' latest round of $115M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's ILiAD Biotechnologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ILiAD Biotechnologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.